OUR TECHNOLOGY

COUR’s platform of immune-modifying nanoparticles treats the root cause of immune-mediated disease, unlike traditional approaches, which rely on toxic immune suppressants or avoidance strategies.


Click here to watch video
on COUR’s reprogramming in autoimmune disease

Cour Nanoparticle Platform
For autoimmune and allergic conditions
COUR’s approach to immune tolerance is based on decades of research from the Stephen D. Miller Lab at Northwestern University. Dr. Miller uncovered the underlying mechanisms of immune tolerance induction and defined a therapeutic approach applicable to a wide range of immune-mediated diseases. Recent human clinical studies of COUR’s lead program, CNP-101, validate this approach.

The nanoparticle surface is functionalized to direct and enhance immune uptake by the mononuclear phagocyte system. The interior core is loaded with disease-specific antigen or allergen for treatment of potentially any autoimmune or allergic condition.

COUR’s nanoparticle platform proactively reprograms the immune system with new instructions that the antigen or allergen is “self,” and the immune response is to be tolerogenic, not inflammatory. This results in targeted reduction of disease specific T cell responses, while leaving the remainder of the immune system intact.

COUR’s nanoparticle therapies deliver disease-specific antigen or allergen to antigen-presenting cells (APCs) in the spleen and liver via natural, non-inflammatory, phagocytic pathways. The APCs engage antigen or allergen specific T cells, which are then deleted, rendered inactive (anergic) or converted to T regulatory cells.